RxDoctor Payments Data

Nana Arkhurst-Arthur

Family · Rocky Mount, NCNPI 1215349154

Payments from drug & device makers

$1,104in general payments, 2019–2025

Across 42 payments — averaging $26.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$277
  • Amgen$183
  • AstraZeneca$173
  • Teva Pharmaceuticals USA, Inc.$130
  • AbbVie$106
  • Lilly USA, LLC$82
  • plus $153 from 5 others

What the payments were for

  • Food & beverage$1,104100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,104 in reported general payments places this provider in the 70th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$18,062
Medicare patients
46
Services billed
244

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide57$80,767
LinzessLinaclotide33$29,474
JardianceEmpagliflozin37$28,748
RybelsusSemaglutide13$26,106
EliquisApixaban31$20,204
JanuviaSitagliptin Phosphate30$14,245
TrulicityDulaglutide13$13,449
Breo ElliptaFluticasone/Vilanterol21$9,030
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df12$7,489
SymbicortBudesonide/Formoterol Fumarate18$4,021
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen43$2,340
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen46$2,201
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,150
Gabapentin112$1,939
Atorvastatin Calcium195$1,641

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$277$106,87270 claims
AbbVieLinzess$106$29,47433 claims
MerckJanuvia$13$14,24530 claims
Lilly USA, LLCTrulicity, Olanzapine$82$13,81134 claims
GSKBreo Ellipta$46$9,03021 claims
AstraZenecaSymbicort$173$4,02118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,522 family providers in North Carolina.

Other family in Rocky Mount

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →